Cangrelor - Reduction of atherothrombotic events
You are here : Home > Formulary Search > Cangrelor - Reduction of atherothrombotic events
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Cangrelor
Indication :
Reduction of atherothrombotic events
Group Name :
Keywords :
NICE, percutaneous coronary intervention, PCI, anti-platelet,
Brand Names Include :
Kengrexal
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Other Indications
Below are listed other indications that Cangrelor is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Reduction of atherothrombotic events .
- No records returned.
Committee Recommendations (1)
NICE TA351 terminated appraisal - Funding will be the responsibility of NHS England. Guidance noted at PCN in October 2015